New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
11:58 EDTNKTR, CTXS, RPRX, SPPI, HLFStocks with increasing implied volatility; HLF RPRX NKTR SPPI CTXS
News For HLF;RPRX;NKTR;SPPI;CTXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 17, 2014
10:45 EDTHLFAckman says Icahn 'stuck holder' of Herbalife due to board position
Subscribe for More Information
10:44 EDTHLFAckman says Herbalife about 7% position in fund
Pershing Square's Bill Ackman is speaking on Bloomberg TV.
10:43 EDTHLFAckman says government 'closer' to intervening in Herbalife
Subscribe for More Information
10:42 EDTHLFAckman says continues to believe Herbalife shares worth zero
Subscribe for More Information
10:42 EDTHLFAckman says Herbalife Q4 results will be worse than Q3
Subscribe for More Information
10:41 EDTHLFAckman says Herbalife business deteriorating
Subscribe for More Information
10:19 EDTHLFHerbalife January and February volatility elevated, shares near 18-month low
Herbalife December call option implied volatility is at 54, January is at 71, February is at 86; compared to its 26-week average of 61 according to Track Data, suggesting large near term price movement.
December 16, 2014
06:03 EDTHLFHerbalife insider trading case dismissed by SEC, NY Post reports
Subscribe for More Information
December 12, 2014
10:01 EDTCTXSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
December 11, 2014
18:03 EDTNKTRNektar reports data from Phase 3 BEACON study of NKTR-102
Nektar Therapeutics presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples. For the 611 evaluable baseline patient samples which yielded CTCs, potential NKTR-102 target-specific pharmacodynamic biomarkers were detected in the majority of samples. The pharmacodynamic biomarkers assessed in the CTC sub-study were chosen because of their potential ability to predict response to topoisomerase inhibition as well as to measure chemo-sensitivity in metastatic cancer patients
16:26 EDTCTXSCitrix initiated with an Underweight at Piper Jaffray
Target $63.
09:35 EDTHLFHerbalife says product claims have 'strict rules and guidelines'
Subscribe for More Information
09:34 EDTHLFVideo entitled 'Harmful Promises' posted to Ackman's Herbalife website
Subscribe for More Information
08:05 EDTNKTRFDA Pediatric Oncologic Subcommittee to hold a meeting
Subscribe for More Information
December 10, 2014
09:35 EDTCTXSCitrix management to meet with William Blair
Subscribe for More Information
December 9, 2014
08:02 EDTNKTRMoventig approved in EU for opioid-induced constipation
Nektar (NKTR) reported partner AstraZeneca (AZN) announced that MOVENTIG has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
07:44 EDTNKTRAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:41 EDTCTXSBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 9 at 10:40 am; not all company presentations may be webcasted. Webcast Link
December 8, 2014
07:29 EDTNKTRUBS to hold investor trip
Subscribe for More Information
07:18 EDTNKTRUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use